Company intelligence / Profile preview
Rallybio
New Haven, Connecticut, United Statesrallybio.com ↗
- Ownership
- Public · RLYB
- Employees
- ~25
- Development stage
- Phase 2
01
Overview
Rallybio is advancing multiple clinical programs, with RLYB212 in Phase 2 for FNAIT prevention and RLYB116 preparing for a confirmatory PK/PD study in 2025. The company has screened over 14,000 pregnant women in its FNAIT natural history study through January 2025.
- Therapeutic areas
- OphthalmologyHematologyImmunologyRare Diseases
- Modalities
- Monoclonal AntibodiesSmall MoleculesAffibody-ABD FusionPegylated Affibody
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $84.5M
- Total revenue
- $858K
- Enterprise value
- $-6.2M
Beyond the preview
Go deeper on Rallybio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rallybio.